Myostatin (GDF-8) is the secreted protein that limits skeletal muscle growth; inhibiting it pharmacologically is one of the longest-running paths to muscle-anabolic therapeutics. The field has produced antibody candidates (bimagrumab, taldefgrobep alfa, apitegromab), ActRII receptor decoys, and an emerging set of synthetic peptide inhibitors — MIF1 and MIF2 peptides derived from the mouse myostatin precursor protein are among the most-cited preclinical examples.
The topic intersects directly with the GLP-1 weight-loss era. Up to 40% of incretin-induced weight loss is attributable to lean mass in the highest-loss patients; Nature Reviews Endocrinology recently flagged sarcopenia and frailty as under-recognized GLP-1 receptor agonist side effects. A 2026 Journal of Cachexia, Sarcopenia and Muscle scoping review consolidated the peptide-therapeutic landscape across muscle-wasting indications, surfacing candidates that could pair with GLP-1 therapy to protect muscle. Regeneron's REGN1033 (trevogrumab) Phase 2 results with semaglutide are due late 2026.
Stories here cover trial readouts, the GLP-1 + muscle-protection thesis, and emerging peptide candidates. See #muscle-wasting, #sarcopenia, and #cachexia.
A 2026 scoping review in the Journal of Cachexia, Sarcopenia and Muscle catalogs peptides studied as therapeutic candidates and biomarkers in skeletal muscle wasting — covering sarcopenia, cancer cachexia, and ICU-related atrophy. The review documents MIF1/MIF2 myostatin peptide inhibitors, cachexia-targeting platform peptides, and the broader role of GH-axis peptides (CJC-1295, ipamorelin, tesamorelin) in muscle homeostasis. The clinical urgency lands harder now than it did pre-2024: Nature Reviews Endocrinology recently flagged sarcopenia and frailty as under-recognized GLP-1 receptor agonist side effects, with up to 40% of GLP-1-induced weight loss attributable to lean mass in the highest-loss patients. The review surfaces non-GLP-1 peptide candidates that could be paired with incretin therapy to protect muscle.
Scholar Rock's apitegromab — a selective pro/latent myostatin antibody approved for SMA — continues to draw obesity-pipeline attention with EMBRAZE Phase 2 data showing 54.9% relative lean mass preservation when combined with tirzepatide vs tirzepatide alone (4.2 lbs / 1.9 kg additional lean mass preserved, p=0.001). Body composition shifted from 70% fat/30% lean with tirzepatide alone to 85%/15% with the combination. SRK-439 next-gen selective myostatin inhibitor is in preclinical development with attenuation of fat-mass rebound after GLP-1 withdrawal as a key signal.
Regeneron's COURAGE Phase 2 data presented at EASD 2025 continue to drive obesity-pipeline conversations. Semaglutide alone produced 6.5% lean mass loss at 26 weeks; sema + trevogrumab 200 mg cut that to 3.3% (~half), and the triplet with garetosmab (anti-activin A) pushed to 2.0% lean mass loss with 92.6% fat-mass loss. The triplet had higher discontinuation for tolerability. Full COURAGE completion is expected late 2026, with Phase 3 initiation likely 2027.